Todd Asset Management LLC Invests $26.32 Million in Smith & Nephew SNATS, Inc. $SNN

Todd Asset Management LLC acquired a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 725,230 shares of the medical equipment provider’s stock, valued at approximately $26,319,000. Todd Asset Management LLC owned approximately 0.17% of Smith & Nephew SNATS as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SNN. Bank of Montreal Can raised its position in Smith & Nephew SNATS by 321.6% during the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after acquiring an additional 2,616,301 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Smith & Nephew SNATS by 6,663.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after purchasing an additional 1,192,755 shares in the last quarter. ABC Arbitrage SA raised its position in shares of Smith & Nephew SNATS by 1,063.4% during the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock worth $27,525,000 after purchasing an additional 821,393 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after buying an additional 583,809 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Smith & Nephew SNATS by 365.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock valued at $19,742,000 after buying an additional 505,934 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of several recent research reports. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Finally, Canaccord Genuity Group decreased their target price on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Smith & Nephew SNATS currently has an average rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Stock Performance

NYSE SNN opened at $36.16 on Monday. Smith & Nephew SNATS, Inc. has a 12 month low of $23.91 and a 12 month high of $38.79. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $33.48 and a 200-day moving average of $34.82.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.